Compare Eli Lilly And Co (LLY) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Msci Inc — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Msci Inc trades at $565.48 (market cap $40.38B). The key difference: Eli Lilly And Co is far larger — about 25.8× Msci Inc's market cap, and Msci Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Msci Inc for 82 Days on average.
| LLY | MSCI | |
|---|---|---|
Market Cap | $1.04T | $40.38B |
Volume | 3,064,878 | 414,140 |
Sector | Health | Financials |
52-Week High | $1.28K | $643.83 |
52-Week Low | $799.57 | $511.84 |
Typical Hold Time | 93 Days | 82 Days |
Enterprise Value | $1.09T | $46.54B |
Dividend Yield | 0.59% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MSCI trades at $563.55, up 1.47% today, with a bullish technical signal and strong fundamentals including 40.73% net income margin and consistent revenue growth. Recent news highlights the completion of the First Street acquisition and upcoming Q3 2026 earnings call, reinforcing its strategic expansion in climate risk analytics.
The outlook is positive with a consensus price target of $701.71, though high valuation ratios and a recent earnings miss pose risks. Long-term growth is supported by recurring revenue streams and market leadership in index and analytics services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
